Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
DRUG-INDUCED REGULATION OF [I-125] IODOCYANOPINDOLOL-LABELED 5-HYDROXYTRYPTAMINE(1B) RECEPTOR-BINDING SITES IN THE CENTRAL-NERVOUS-SYSTEM
Autore:
PRANZATELLI MR; RAZI P;
Indirizzi:
CHILDRENS RES INST,CTR NEUROSCI,MOVEMENT DISORDER PHARMACOL LAB,111 MICHIGAN AVE NW WASHINGTON DC 20010 GEORGE WASHINGTON UNIV,DEPT NEUROL WASHINGTON DC 00000 GEORGE WASHINGTON UNIV,DEPT PEDIAT WASHINGTON DC 20052 GEORGE WASHINGTON UNIV,DEPT PHARMACOL WASHINGTON DC 20052
Titolo Testata:
Neuropsychopharmacology
fascicolo: 4, volume: 10, anno: 1994,
pagine: 259 - 264
SICI:
0893-133X(1994)10:4<259:DRO[I5>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
RAT FRONTAL-CORTEX; LOCOMOTOR-ACTIVITY; I-125 IODOCYANOPINDOLOL; SEROTONIN RECEPTORS; AGONIST 8-OH-DPAT; RECOGNITION SITES; 5-HT1C RECEPTORS; BRAIN MEMBRANES; DOWN-REGULATION; H-3 5-HT;
Keywords:
SEROTONIN(1B) RECEPTOR; [I-125] ICYP; RU 24969; M-CPP; TOLERANCE; 5-HT1B SITES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
34
Recensione:
Indirizzi per estratti:
Citazione:
M.R. Pranzatelli e P. Razi, "DRUG-INDUCED REGULATION OF [I-125] IODOCYANOPINDOLOL-LABELED 5-HYDROXYTRYPTAMINE(1B) RECEPTOR-BINDING SITES IN THE CENTRAL-NERVOUS-SYSTEM", Neuropsychopharmacology, 10(4), 1994, pp. 259-264

Abstract

Little is known about the regulation of 5-hydroxytryptamine(1B) (5-HT1B) receptors, a putative terminal autoreceptor in the central nervoussystem. We studied the regional responses of [I-125]iodocyanopindolol([I-125]ICYP)-labeled central 5-HT1B sites to chronic treatment with S-HT agonists and antagonists at a dose of 10 mg/kg/d IP for 30 consecutive days in the rat. In controls, there were 3.4-fold regional differences in B-max, with a rank order of brainstem > hippocampus > cortex, striatum > spinal cord, and K(a)s were slightly lower in striatum and spinal cord. RU 24969 significantly reduced B-max 23 to 63% in cortex, hippocampus, striatum, brainstem, and spinal cord without a change in K-a except for a 1.7-fold increase in cortex and spinal cord. The putative 5-H-1B agonist (m-trifluoromethylphenylpiperazine (TFMPP), butnot [1-(3-chlorophenyl)piperazine] (m-CPP) or the 5-HT1B antagonists pindolol or quipazine, reduced the B-max of cortical 5-HT1B sites (-16%). Chronic treatment with the 5-HT antagonists methysergide, pindolol, propranolol, ritanserin, metergoline, or methiothepin did not significantly affect striatal B-max or K-d compared to respective vehicles. The data demonstrate significant changes in maximum number of 5-HT1B receptors in response to chronic agonist but not antagonist treatments at the dose studied.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 00:40:51